Holen Sie sich die Stockscreener-App
23.06
3.47%
-0.83
Handel nachbörslich:
23.06
Schlusskurs vom Vortag:
$23.89
Offen:
$23.35
24-Stunden-Volumen:
323.29K
Relative Volume:
1.58
Marktkapitalisierung:
$635.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.47M
KGV:
-4.1198
EPS:
-5.5973
Netto-Cashflow:
$-73.92M
1W Leistung:
+12.93%
1M Leistung:
-9.39%
6M Leistung:
-15.38%
1J Leistung:
+15.76%
1-Tages-Spanne:
$21.91
$23.40
1-Wochen-Bereich:
$17.82
$24.39
52-Wochen-Spanne:
$14.42
$38.93
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Firmenname
Lenz Therapeutics Inc
Sektor
Branche
Telefon
858-925-7000
Adresse
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Vergleichen Sie LENZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
23.06 | 635.14M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.89 | 124.91B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.28 | 60.05B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
587.59 | 35.88B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
230.50 | 29.83B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
228.14 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-03-18 | Eingeleitet | TD Cowen | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Outperform |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-04-10 | Eingeleitet | Citigroup | Buy |
| 2024-03-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-25 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-01-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-14 | Eingeleitet | BTIG Research | Buy |
| 2022-03-22 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-07-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Lenz Therapeutics Inc Aktie (LENZ) Neueste Nachrichten
LENZ Therapeutics (NASDAQ:LENZ) Now Covered by Analysts at Piper Sandler - Defense World
Form 424B3 LENZ Therapeutics, Inc. - StreetInsider
Piper Sandler raises LENZ Therapeutics stock to Overweight - Investing.com Australia
Piper Sandler raises LENZ Therapeutics stock to Overweight By Investing.com - Investing.com Canada
Piper Sandler Projects Strong Growth for Lenz Therapeutics (LENZ) with LNZ100 | ABBV Stock News - GuruFocus
Wellington Management Group LLP Has $815,000 Stock Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Bought by Vanguard Group Inc. - Defense World
KLP Kapitalforvaltning AS Makes New $46,000 Investment in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of “Buy” by Brokerages - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Bought by American Century Companies Inc. - Defense World
8,485 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Bought by Raymond James Financial Inc. - Defense World
LENZ Therapeutics: Freedom From Reading Glasses (NASDAQ:LENZ) - Seeking Alpha
Presbyopia Treatment Market Size in 7MM is expected to grow at - openPR.com
18,900 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Purchased by Swiss National Bank - Defense World
Swiss National Bank Takes $546,000 Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
LENZ Therapeutics Stock Is Attractive Before PDUFA (NASDAQ:LENZ) - Seeking Alpha
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Lowers Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Brokers Issue Forecasts for LENZ Q2 Earnings - Defense World
What is Leerink Partnrs’ Forecast for LENZ Q1 Earnings? - Defense World
William Blair Issues Negative Outlook for LENZ Earnings - Defense World
LENZ Therapeutics (NASDAQ:LENZ) Price Target Raised to $47.00 - Defense World
Equities Analysts Offer Predictions for LENZ FY2026 Earnings - Defense World
What is HC Wainwright’s Estimate for LENZ Q1 Earnings? - Defense World
Lenz Therapeutics’ Earnings Call Highlights Positive Outlook - TipRanks
Promising Outlook for LENZ Therapeutics: Buy Rating Affirmed Amid Strong Market Position and Upcoming Product Launch - TipRanks
Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) PT at $35.40 - Defense World
Citi raises LENZ Therapeutics price target to $47, keeps Buy rating - Investing.com Australia
LENZ Therapeutics stock holds $38 target on FDA approval optimism By Investing.com - Investing.com Australia
LENZ Therapeutics stock holds $38 target on FDA approval optimism - Investing.com
Citi ups PT on LENZ Therapeutics on eye-drop approval confidence - TradingView
Lenz Therapeutics outlines Q4 2025 launch plans for LNZ100 amid FDA review progress - MSN
Earnings call transcript: LENZ Therapeutics Q4 2024 shows innovation drive - Investing.com India
Earnings call transcript: LENZ Therapeutics Q4 2024 shows innovation drive By Investing.com - Investing.com UK
LENZ Therapeutics, Inc. SEC 10-K Report - TradingView
LENZ THERAPEUTICS Earnings Results: $LENZ Reports Quarterly Earnings - Nasdaq
LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - The Manila Times
LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent ... - The Bakersfield Californian
LENZ Therapeutics (NASDAQ:LENZ) Now Covered by TD Cowen - Defense World
TD Cowen lifts LENZ Therapeutics stock to buy, sets $60 target - Investing.com Canada
TD Cowen lifts LENZ Therapeutics stock to buy, sets $60 target By Investing.com - Investing.com South Africa
TD Cowen Initiates LENZ Therapeutics at Buy With $60 Price Target -March 18, 2025 at 07:09 am EDT - Marketscreener.com
American Electric Power, Block and Lenz Therapeutics - TradingView
LENZ THERAPEUTICS Earnings Preview: Recent $LENZ Insider Trading, Hedge Fund Activity, and More - Nasdaq
LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025 - The Manila Times
LENZ Therapeutics Q4 Earnings: Key Updates Coming on Presbyopia Eye Drops - StockTitan
Rhumbline Advisers Boosts Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics to Host Commercial Day on April 15, 2025 - The Manila Times
Will LENZ's Presbyopia Eye Drop Disrupt the Vision Care Market? Commercial Strategy Reveal Coming - StockTitan
Insiders Enjoy US$227k Return After Buying LENZ Therapeutics Stock - Simply Wall St
Finanzdaten der Lenz Therapeutics Inc-Aktie (LENZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lenz Therapeutics Inc-Aktie (LENZ) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Schimmelpennink Evert B. | President, CEO and Secretary |
Mar 07 '25 |
Option Exercise |
1.04 |
4,200 |
4,368 |
49,200 |
| Olsson Shawn | Chief Commercial Officer |
Dec 16 '24 |
Option Exercise |
2.08 |
3,333 |
6,933 |
3,333 |
| Schimmelpennink Evert B. | President, CEO and Secretary |
Jul 22 '24 |
Option Exercise |
1.04 |
45,000 |
46,800 |
45,000 |
| Chevallard Daniel R. | Chief Financial Officer |
May 14 '24 |
Buy |
15.68 |
3,188 |
49,988 |
3,188 |
| MCCOLLUM JAMES W | Director |
May 13 '24 |
Buy |
15.99 |
31,332 |
501,093 |
525,565 |
0.21%
1.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):